Krystal Biotech, INC 10-Q quarterly reports

Krystal Biotech announces significant revenue growth driven by VYJUVEK sales and advances in its diverse gene therapy pipeline.

Krystal Biotech announces a 32% year-over-year increase in product revenue for Q1 2026, driven by strong VYJUVEK sales, and provides updates on its diverse gene therapy pipeline.

Krystal Biotech reports significant revenue growth and net income for Q3 and nine months ended September 30, 2025, driven by strong VYJUVEK sales and a deferred tax asset release.

Krystal Biotech reports strong Q2 2025 financial results, driven by VYJUVEK sales and recent global regulatory approvals in Europe and Japan.

Krystal Biotech's Q1 2025 revenue surged to $88.2 million, driven by increased sales of VYJUVEK after its FDA and European Commission approvals.

Krystal Biotech's Q3 2024 results show significant revenue growth driven by VYJUVEK sales, reaching $83.8 million for the quarter.

Krystal Biotech's Q2 2024 results show significant revenue growth driven by VYJUVEK sales, achieving profitability for the quarter.

Krystal Biotech's first quarter of 2024 saw a net income of $932,000, driven by $45.3 million in net product revenue from VYJUVEK.